TRPA1 and central nervous system cancer: The effects were reversed by pretreatment of glioma cells with the TRPA1 antagonist, as opposed to the temozolomide (TMZ) therapy, which had a lower impact on the production of mitochondrial ROS and cell apoptosis [66].